uniQure N.V. $QURE Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered its position in uniQure N.V. (NASDAQ:QURE) by 36.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,149,351 shares of the biotechnology company’s stock after selling 658,334 shares during the quarter. JPMorgan Chase & Co. owned approximately 2.09% of uniQure worth $67,088,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of QURE. Jefferies Financial Group Inc. acquired a new stake in shares of uniQure in the 2nd quarter valued at $29,217,000. Sofinnova Investments Inc. increased its holdings in uniQure by 185.5% in the second quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock valued at $21,723,000 after buying an additional 1,012,585 shares during the last quarter. Balyasny Asset Management L.P. raised its stake in uniQure by 2,054.1% in the second quarter. Balyasny Asset Management L.P. now owns 536,968 shares of the biotechnology company’s stock valued at $7,485,000 after buying an additional 512,040 shares in the last quarter. Ameriprise Financial Inc. raised its stake in uniQure by 38.6% in the second quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock valued at $10,622,000 after buying an additional 212,218 shares in the last quarter. Finally, Aberdeen Group plc lifted its holdings in uniQure by 6.9% during the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock worth $171,593,000 after buying an additional 189,029 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on QURE. Mizuho dropped their price objective on uniQure from $60.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, December 8th. Chardan Capital reaffirmed a “buy” rating and issued a $53.00 price target on shares of uniQure in a report on Thursday, December 4th. Wells Fargo & Company dropped their price target on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 12th. The Goldman Sachs Group reduced their price objective on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a research report on Tuesday, November 4th. Finally, Stifel Nicolaus lowered their target price on shares of uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, December 11th. Ten research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, uniQure has an average rating of “Moderate Buy” and an average target price of $58.33.

uniQure Price Performance

Shares of NASDAQ QURE opened at $24.03 on Wednesday. The stock has a market cap of $1.50 billion, a P/E ratio of -5.47 and a beta of 0.66. uniQure N.V. has a twelve month low of $7.76 and a twelve month high of $71.50. The stock has a 50 day moving average of $23.72 and a two-hundred day moving average of $29.70. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Scheduled catalyst — uniQure will report Q4 and full‑year 2025 results before the market opens on March 2, 2026 and host a conference call; this gives investors a near‑term event to reassess revenue, expenses and guidance. uniQure to Announce 2025 Financial Results
• Neutral Sentiment: Analyst initiation — Wolfe Research initiated coverage of uniQure with a “peer perform” (market/sector‑perform) rating, which is neutral and unlikely to provide a strong near‑term positive catalyst. Wolfe Research initiates coverage
• Negative Sentiment: Multiple law firms have filed or are soliciting lead plaintiffs for securities class actions covering the September 24–October 31, 2025 period; increased litigation risk typically depresses sentiment and can pressure the stock. Example notices from Kessler Topaz and others were published today. QURE Investor Alert: Kessler Topaz Meltzer & Check, LLP
• Negative Sentiment: Additional plaintiff‑firm solicitations/press releases (Rosen, Pomerantz, Faruqi & Faruqi, Schall, Berger Montague, Gross, Levi & Korsinsky, DJS, etc.) amplify legal headlines and may deter institutional buyers until legal exposure is clearer. ROSEN encourages investors to secure counsel
• Negative Sentiment: The volume of notices and the April 13, 2026 lead‑plaintiff deadline being highlighted across firms creates headline risk; even without merits assessed, investor uncertainty from potential settlements, legal costs or management distraction can weigh on share price. Pomerantz investor alert

Insider Buying and Selling at uniQure

In other uniQure news, Director Robert Gut sold 25,613 shares of uniQure stock in a transaction on Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the transaction, the director directly owned 32,342 shares in the company, valued at approximately $796,260.04. The trade was a 44.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the sale, the director directly owned 20,439 shares of the company’s stock, valued at $557,575.92. The trade was a 23.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 4.79% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.